HMGB1 and neoplasm: This effect may be attributed to the upregulation of CRT and HMGB1, which potentially enhances tumor cell phagocytosis, stimulates the infiltration of effector immune cells, and synergizes with PD-L1 inhibition to effectively impede tumor progression.